Hinge Health, Inc. (NYSE:HNGE) filed an 8-K on November 2, 2026, disclosing that President James Pursley notified the company of his resignation effective January 1, 2027, his subsequent appointment to the Board of Directors effective January 4, 2027, and the appointment of Co-Founder and CEO Daniel Perez to also serve as President, alongside Q3 2026 financial results.

Key Highlights

  • Pursley resignation: James Pursley notified the company on October 29, 2026 of his intent to resign as President, effective January 1, 2027, with no disagreement cited over company operations, policies, or practices.
  • Board expansion: The Board increased its size from six to seven directors and appointed Pursley as a Class II director, effective January 4, 2027, with a term expiring at the 2027 annual meeting of stockholders.
  • Director compensation: Pursley will receive an annual cash retainer of $40,000 for Board service; he has waived all equity compensation under the Director Compensation Program while serving under the Advisor Agreement.
  • Advisor Agreement: Signed October 30, 2026, the agreement provides Pursley an anticipated grant of 40,000 RSUs vesting in 16 equal quarterly installments over four years following February 1, 2027, subject to Compensation Committee approval and continued service.
  • Perez named President: Daniel Perez, Co-Founder and CEO, was appointed President effective January 1, 2027, with no additional compensation for the new role.
  • Q3 2026 results announced: The company issued a press release on November 2, 2026 announcing financial results for the third quarter ended September 30, 2026, with a conference call held at 1:30 p.m. Pacific time the same day.

Leadership Transition at Hinge Health: Pursley Exits Executive Role, Joins Board

According to the filing, James Pursley notified Hinge Health, Inc. on October 29, 2026 of his intention to resign as President, with the resignation taking effect on January 1, 2027 (the "Resignation Date"). The company stated that Pursley's decision "was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices," and that he will assist with the transition of his responsibilities ahead of that date.

Following a recommendation by the Nominating and Corporate Governance Committee, the Board approved an increase in its size from six to seven directors and appointed Pursley to serve as a Class II director, effective January 4, 2027. The filing noted that, as of the time of filing, the Board does not expect to appoint Pursley to any Board committees. Pursley will be eligible to receive an annual cash retainer of $40,000 under the company's Non-Employee Director Compensation Program, but has waived all equity compensation - including initial and annual RSU awards - while providing services under the Advisor Agreement.

Under the Advisor Agreement dated October 30, 2026, Pursley is entitled to a grant of 40,000 RSUs, subject to Compensation Committee approval. The RSUs would vest in sixteen equal quarterly installments over the four years following February 1, 2027, with the first installment vesting on May 1, 2027, conditioned on continued service under the agreement. In connection with Pursley's departure from the President role, the Board appointed Daniel Perez, the company's Co-Founder and Chief Executive Officer, to also hold the title of President effective January 1, 2027. The filing stated that Perez will not receive any additional compensation for serving as President.

What Was Disclosed

Hinge Health's 8-K disclosed the resignation of President James Pursley effective January 1, 2027, his appointment as a Class II Board director effective January 4, 2027, an Advisor Agreement granting up to 40,000 RSUs subject to committee approval, the appointment of CEO Daniel Perez as President without additional pay, and Q3 2026 financial results.